Thomas Jacob1, Joe W Gray1,2,3, Megan Troxell3,4,5, Tania Q Vu6,7,8. 1. Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, 97201, USA. 2. OHSU Center for Spatial Systems Bioscience, Portland, OR, 97201, USA. 3. The Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA. 4. Department of Pathology, Oregon Health & Science University, Portland, OR, 97239, USA. 5. Department of Pathology, Stanford University Medical Center, Stanford, CA, 94305, USA. 6. Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, 97201, USA. vuta@ohsu.edu. 7. OHSU Center for Spatial Systems Bioscience, Portland, OR, 97201, USA. vuta@ohsu.edu. 8. The Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA. vuta@ohsu.edu.
Abstract
PURPOSE: Activating genetic changes in the phosphatidylinositol-3-kinase (PI3K) signaling pathway are found in over half of invasive breast cancers (IBCs). Previously, we discovered numerous hotspot PIK3CA mutations in proliferative breast lesions. Here, we investigate the spatial nature of PI3K pathway signaling and its relationship with PI3K genotype in breast lesions. METHODS: We identified PI3K phosphosignaling network signatures in columnar cell change (CCL), usual ductal hyperplasia (UDH), ductal carcinoma in situ (DCIS), and IBC in 26 lesions of known PIK3CA genotype from 10 human breast specimens using a hyperspectral-based multiplexed tissue imaging platform (MTIP) to simultaneously quantitate PI3K/MAPK pathway targets (pAKT473, pAKT308, pPRAS40, pS6, and pERK) in FFPE tissue, with single-cell resolution. RESULTS: We found that breast lesional epithelia contained spatially heterogeneous patterns of PI3K pathway phosphoprotein signatures, even within microscopic areas of CCL, UDH, DCIS, and IBC. Most lesions contained 3-12 unique phosphoprotein signatures within the same microscopic field. The dominant phosphoprotein signature for each lesion was not well correlated with lesion genotype or lesion histology, yet samples from the same patient tended to group together. Further, 5 UDH/CCL lesions across different patients had a common phosphosignature at the epithelial-stromal interface (possible myoepithelial cells) that was distinct from both the adjacent lesional epithelium and distinct from adjacent stroma. CONCLUSION: We present the first spatial mapping of PI3K phosphoprotein networks in proliferative breast lesions and demonstrate complex PI3K signaling heterogeneity that defies simple correlation between PIK3CA genotype and phosphosignal pattern.
PURPOSE: Activating genetic changes in the phosphatidylinositol-3-kinase (PI3K) signaling pathway are found in over half of invasive breast cancers (IBCs). Previously, we discovered numerous hotspot PIK3CA mutations in proliferative breast lesions. Here, we investigate the spatial nature of PI3K pathway signaling and its relationship with PI3K genotype in breast lesions. METHODS: We identified PI3K phosphosignaling network signatures in columnar cell change (CCL), usual ductal hyperplasia (UDH), ductal carcinoma in situ (DCIS), and IBC in 26 lesions of known PIK3CA genotype from 10 human breast specimens using a hyperspectral-based multiplexed tissue imaging platform (MTIP) to simultaneously quantitate PI3K/MAPK pathway targets (pAKT473, pAKT308, pPRAS40, pS6, and pERK) in FFPE tissue, with single-cell resolution. RESULTS: We found that breast lesional epithelia contained spatially heterogeneous patterns of PI3K pathway phosphoprotein signatures, even within microscopic areas of CCL, UDH, DCIS, and IBC. Most lesions contained 3-12 unique phosphoprotein signatures within the same microscopic field. The dominant phosphoprotein signature for each lesion was not well correlated with lesion genotype or lesion histology, yet samples from the same patient tended to group together. Further, 5 UDH/CCL lesions across different patients had a common phosphosignature at the epithelial-stromal interface (possible myoepithelial cells) that was distinct from both the adjacent lesional epithelium and distinct from adjacent stroma. CONCLUSION: We present the first spatial mapping of PI3K phosphoprotein networks in proliferative breast lesions and demonstrate complex PI3K signaling heterogeneity that defies simple correlation between PIK3CA genotype and phosphosignal pattern.
Authors: Turgut Dogruluk; Yiu Huen Tsang; Maribel Espitia; Fengju Chen; Tenghui Chen; Zechen Chong; Vivek Appadurai; Armel Dogruluk; Agna Karina Eterovic; Penelope E Bonnen; Chad J Creighton; Ken Chen; Gordon B Mills; Kenneth L Scott Journal: Cancer Res Date: 2015-12-01 Impact factor: 12.701
Authors: Stephan W Jahn; Karl Kashofer; Andrea Thüringer; Luca Abete; Elke Winter; Sylvia Eidenhammer; Christian Viertler; Fattaneh Tavassoli; Farid Moinfar Journal: Am J Pathol Date: 2016-01 Impact factor: 4.307
Authors: Alexander Miron; Maria Varadi; Daniel Carrasco; Hailun Li; Lauren Luongo; Hee Jung Kim; So Yeon Park; Eun Yoon Cho; Gretchen Lewis; Sarah Kehoe; J Dirk Iglehart; Deborah Dillon; D Craig Allred; Laura Macconaill; Rebecca Gelman; Kornelia Polyak Journal: Cancer Res Date: 2010-06-15 Impact factor: 12.701
Authors: Jennifer Dunlap; Claudia Le; Arielle Shukla; Janice Patterson; Ajia Presnell; Michael C Heinrich; Christopher L Corless; Megan L Troxell Journal: Breast Cancer Res Treat Date: 2009-05-06 Impact factor: 4.872
Authors: Daniel M Spagnolo; Yousef Al-Kofahi; Peihong Zhu; Timothy R Lezon; Albert Gough; Andrew M Stern; Adrian V Lee; Fiona Ginty; Brion Sarachan; D Lansing Taylor; S Chakra Chennubhotla Journal: Cancer Res Date: 2017-11-01 Impact factor: 12.701